Vanguard Group
ENZ

Vanguard Group’s Enzo Biochem, Inc. ENZ Stock Holding History

Vanguard Group’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,859,002
Closed -$688K – 4355
2025
Q1 		$688K Hold
1,859,002
– – ﹤0.01% 3813
2024
Q4 		$1.33M Sell
1,859,002
-17,620
-0.9% -$18.3K ﹤0.01% 3674
2024
Q3 		$2.1M Hold
1,876,622
– – ﹤0.01% 3545
2024
Q2 		$2.05M Hold
1,876,622
– – ﹤0.01% 3548
2024
Q1 		$2.38M Hold
1,876,622
– – ﹤0.01% 3535
2023
Q4 		$2.61M Buy
1,876,622
+147,538
+9% +$196K ﹤0.01% 3508
2023
Q3 		$2.42M Hold
1,729,084
– – ﹤0.01% 3522
2023
Q2 		$3.18M Sell
1,729,084
-42,587
-2% -$98.6K ﹤0.01% 3498
2023
Q1 		$4.31M Hold
1,771,671
– – ﹤0.01% 3378
2022
Q4 		$2.53M Buy
1,771,671
+922
+0.1% +$1.8K ﹤0.01% 3580
2022
Q3 		$3.95M Hold
1,770,749
– – ﹤0.01% 3441
2022
Q2 		$3.67M Hold
1,770,749
– – ﹤0.01% 3531
2022
Q1 		$5.14M Sell
1,770,749
-12,299
-0.7% -$39.5K ﹤0.01% 3516
2021
Q4 		$5.72M Sell
1,783,048
-227,248
-11% -$775K ﹤0.01% 3530
2021
Q3 		$7.12M Hold
2,010,296
– – ﹤0.01% 3441
2021
Q2 		$6.37M Sell
2,010,296
-374,913
-16% -$1.18M ﹤0.01% 3459
2021
Q1 		$8.21M Sell
2,385,209
-12,589
-0.5% -$39.2K ﹤0.01% 3261
2020
Q4 		$6.04M Buy
2,397,798
+16,961
+0.7% +$36.9K ﹤0.01% 3269
2020
Q3 		$5.02M Sell
2,380,837
-6,374
-0.3% -$15.1K ﹤0.01% 3141
2020
Q2 		$5.35M Buy
2,387,211
+128,460
+6% +$330K ﹤0.01% 3065
2020
Q1 		$5.71M Buy
2,258,751
+99,911
+5% +$245K ﹤0.01% 2911
2019
Q4 		$5.68M Sell
2,158,840
-4,192
-0.2% -$12.5K ﹤0.01% 3129
2019
Q3 		$7.79M Sell
2,163,032
-92,654
-4% -$328K ﹤0.01% 2946
2019
Q2 		$7.6M Buy
2,255,686
+88,589
+4% +$312K ﹤0.01% 3002
2019
Q1 		$5.92M Buy
2,167,097
+818,071
+61% +$2.68M ﹤0.01% 3079
2018
Q4 		$3.75M Sell
1,349,026
-1,366,372
-50% -$4.48M ﹤0.01% 3186
2018
Q3 		$11.2M Buy
2,715,398
+565,126
+26% +$2.57M ﹤0.01% 2864
2018
Q2 		$11.2M Buy
2,150,272
+156,908
+8% +$956K ﹤0.01% 2851
2018
Q1 		$10.9M Buy
1,993,364
+93,237
+5% +$657K ﹤0.01% 2789
2017
Q4 		$15.5M Buy
1,900,127
+7,635
+0.4% +$72.9K ﹤0.01% 2610
2017
Q3 		$19.8M Buy
1,892,492
+139,812
+8% +$1.55M ﹤0.01% 2493
2017
Q2 		$19.4M Buy
1,752,680
+86,922
+5% +$810K ﹤0.01% 2473
2017
Q1 		$13.9M Buy
1,665,758
+139,901
+9% +$986K ﹤0.01% 2604
2016
Q4 		$10.6M Buy
1,525,857
+41,998
+3% +$268K ﹤0.01% 2720
2016
Q3 		$7.55M Sell
1,483,859
-11,074
-0.7% -$66.1K ﹤0.01% 2807
2016
Q2 		$8.93M Buy
1,494,933
+159,423
+12% +$885K ﹤0.01% 2704
2016
Q1 		$6.08M Buy
1,335,510
+60,599
+5% +$270K ﹤0.01% 2863
2015
Q4 		$5.74M Buy
1,274,911
+10,656
+0.8% +$45K ﹤0.01% 2928
2015
Q3 		$4.01M Buy
1,264,255
+39,390
+3% +$120K ﹤0.01% 3069
2015
Q2 		$3.71M Buy
1,224,865
+85,823
+8% +$241K ﹤0.01% 3149
2015
Q1 		$3.36M Buy
1,139,042
+32,076
+3% +$105K ﹤0.01% 3190
2014
Q4 		$4.92M Buy
1,106,966
+7,218
+0.7% +$34.4K ﹤0.01% 2910
2014
Q3 		$5.66M Buy
1,099,748
+22,021
+2% +$117K ﹤0.01% 2760
2014
Q2 		$5.66M Buy
1,077,727
+111,276
+12% +$481K ﹤0.01% 2774
2014
Q1 		$4.02M Buy
966,451
+118,186
+14% +$405K ﹤0.01% 2937
2013
Q4 		$2.48M Buy
848,265
+29,453
+4% +$73K ﹤0.01% 3106
2013
Q3 		$2.06M Buy
818,812
+86,091
+12% +$204K ﹤0.01% 3120
2013
Q2 		$1.52M Buy
+732,721
New +$1.62M ﹤0.01% 3164

Other funds holding ENZ

RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
KCM
Kempner Capital Management Galveston, Texas $106M AUM 29.1% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

Vanguard Group's ENZ Position: Q2 2025 in Review

Vanguard Group sold out of Enzo Biochem, Inc. (ENZ) in Q2 2025, closing a stake of 1,859,002 shares — an estimated $688K sold.

Vanguard Group first reported a position in ENZ in Q2 2013 and held it in 48 quarters. The position peaked at $19.8M in Q3 2017. 6 funds tracked by Wall St. Rank hold ENZ as of Q2 2025.

  • Vanguard Group reported no remaining Enzo Biochem, Inc. position as of Q2 2025 after selling out during the quarter.
  • Vanguard Group sold 1,859,002 Enzo Biochem, Inc. shares in Q2 2025, an estimated $688K.
  • Vanguard Group first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 48 quarters.
  • Vanguard Group's Enzo Biochem, Inc. position peaked at $19.8M in Q3 2017.
  • 6 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2025.

Based on Vanguard Group's 13F filing for Q2 2025, filed 11 Aug 2025.